Appointment of Managing Director
Summary by AI BETAClose X
13 November 2026
BEXIMCO PHARMACEUTICALS PLC.
Appointment of Managing Director
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that Chief Operating Officer, S. M. Rabbur Reza, has been appointed as Managing Director for a period of five years with immediate effect.
This follows the Company’s previous announcement dated 30 September 2026 which announced the departure of Mr Iqbal Ahmed from the role, who will continue to serve as a non-executive Director. The appointment will be subject to the approval of the Shareholders at the next Annual General Meeting of the Company.
Rabbur Reza has been Chief Operating Officer at Beximco Pharmaceuticals PLC since 2009, with over 30 years of experience in the pharmaceutical industry, spanning international business development, operations, strategy, and leadership. During his tenure at the Company, he has played a key role in expanding the Company’s exports to over 60 countries, including the USA, Australia, and markets across Europe, and in driving the strategic acquisitions of Nuvista Pharma and Sanofi Bangladesh (now Synovia Pharma). He also pioneered the introduction of first-to-market generic medicines, including breakthrough treatments for hepatitis C and COVID-19, and led the introduction of specialty generics and innovative therapies, including the 2026 launch of Triko, the first generic version of Vertex Pharmaceuticals’ breakthrough cystic fibrosis therapy Trikafta.
He holds a Bachelor of Pharmacy degree from Panjab University, India, and an MBA from Queensland University of Technology, Australia. He has also completed executive education programmes at Harvard Business School, London Business School, and MIT Sloan School of Management. Rabbur Reza is an Executive Committee Member of the Bangladesh Association of Pharmaceutical Industries (BAPI) and a member of the Medical Technical Options Committee under the Montreal Protocol.
A S F Rahman, Chairman of Beximco Pharma, commented:
“We are delighted to announce Rabbur Reza’s appointment as Managing Director. Throughout his time at the Company, he has demonstrated his exceptional leadership skills and industry expertise which have been central to the Company’s continued growth and success as a globally recognised pharmaceutical business. Rabbur’s efforts have consistently delivered for both patients and shareholders, and we look forward to seeing continued progress of Beximco Pharma under his leadership.”
Rabbur Reza, Managing Director of Beximco Pharma, added:
“I am honoured to be appointed Managing Director and want to thank the Board for trusting me with this opportunity. I have spent more than 25 years at Beximco Pharma and I am incredibly excited to step into this new role as we continue to expand our work to deliver high-quality, affordable medicines to more people around the world.”
Additional disclosure information required by Schedule 2(g) of the AIM Rules for Companies
Sharif Mohammad Rabbur Reza
Mr. Reza, aged 58, excluding certain Beximco Pharma subsidiaries, is currently a director of Biocare Manufacturing SDN BHD, and has not held any other directorships or partnerships in the past five years.
Mr. Reza holds 550 ordinary shares (representing 0.00%) in the capital of the Company.
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S M Rabbur Reza, Managing Director
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Ben Atwell / Sam Purewal / Lucy Molloy
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company’s broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma’s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund